Practical methods for analysing ordinal outcome data in clinical trials

References - methodology

Agresti A (2002). *Categorical Data Analysis* (Second Edition). Wiley: New York.

Armitage P (1955). Tests for linear trends in proportions and frequencies. *Biometrics 11,* 375-386.

Ashby D, Pocock SJ, Shaper AG (1986). Ordered polytomous regression: an example relating serum biochemistry and haematology to alcohol consumption. *Applied Statistics 35,* 289-301.

Bolland K, Sooriyarachchi MR, Whitehead J (1998). Sample size review in a head injury trial with ordered categorical responses. *Statistics in Medicine*. 17, 2835-2847.

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010). A basic introduction to fixed-effect and random-effects models for meta-analysis. *Research Synthesis Methods* 1(2), 97-111.

Brant R (1990). Assessing proportionality in the proportional odds model for ordinal logisitic regression. *Biometrics* 46, 1171-1178.

Cohen J (1983). The Cost of Dichotomization. *Applied Psychological Measurement* 7(3):249-253.

Gøtzsche PC (2001). Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Annals of the Rheumatic Diseases* 60, 349-352.

Gould AL (1992). Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. *Statistics in Medicine* 11, 55-66.

Gould AL (1995). Planning and revising the sample size for a trial. *Statistics in Medicine 14*, 1039-1051.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. *BMJ* 327, 557-560.

Hilton J, Mehta, CR (1993). Power and sample size calculations for exact conditional tests with ordered categorical data. *Biometrics 49*, 609-616.

Hilton JF (1996). The appropriateness of the Wilcoxon test in ordinal data. *Statistics in Medicine 15,* 631-645.

Hosmer DW, Lemeshow S (1980). Goodness-of-fit tests for the multiple logistic regression model. *Communications in Statistics* A9, 1043-1069.

Jones D, Whitehead J (1979). Sequential forms of the log rank and modified Wilcoxon tests for censored data. *Biometrika 68*, 105-113. And CORRECTION (1981). *Biometrika 68*, 576. [Correction is to censored case only].

Julious SA, Campbell MJ (1996). Letter to the Editor: "Sample sizes calculations for ordered categorical data by J. Whitehead, Statistics in Medicine, 12, 2257–2272 (1993)". *Statistics in Medicine* 15, 1065–1066.

Julious SA, Campbell MJ (1998). Sample size calculations for paired or matched ordinal data. *Statistics in Medicine 17,* 1635-1642.

Kolassa JE (1995). A comparison of size and power calculations for the Wilcoxon statistic for ordered categorical data. *Statistics in Medicine 14,* 1577-1581.

Lesaffre E, Scheys I, Fröhlich J, Bluhmki E (1993). Calculation of power and sample size with bounded outcome scores. *Statistics in Medicine 12*, 1063-1078.

Lipsitz SR, Fitzmaurice GM, Molenberghs G (1996). Goodness-of-fit tests for ordinal response regression models. *Applied Statistics 45,* 175-190.

McCullagh P (1980). Regression models for ordinal data. *Journal of the Royal Statistical Society B 43,* 109-142.

McCullagh P, Nelder J (1989). *Generalised Linear Models*, (2nd Edition). London: Chapman and Hall.

McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, Weir J, Maas AI, Murray GD (2010). A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project, *Clinical Trials* 7, 44-57.

Machado SG, Murray GD, Teasdale GM (1999). Evaluation of designs for clinical trials of neuroprotective agents in head injury. European Brain Injury Consortium. *J Neurotrauma* 16(12):1131-1138.

Mann HB, Whitney DR (1947). On a test of whether one of two variables is stochastically larger. *Annals of Mathematical Statistics 33*, 498-512.

Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, Maas AI, Marmarou A, Mendelow AD, Steyerberg EW, Taylor GS, Teasdale GM, Weir CJ (2005). Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. *Journal of Neurotrauma* 22(5):511-517.

Optimising Analysis of Stroke Trials Collaboration (2008). Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. *International Journal of Stroke* 3(2), 78-84.

Peterson B, Harrell FE (1990). Partial proportional odds models for ordinal response variables. *Applied Statistics 39,* 205-217.

Scharfstein DO, Tsiatis AA, Robins JM (1997). Semiparametric efficiency and its implication on design and analysis of group-sequential studies. *Journal of the American Statistical Association* 92, 1342-1350.

Siegel S (1956). *Nonparametric Statistics for the Behavioural Sciences*. New York: McGraw-Hill.

Whitehead A. (2002). *Meta-analysis of Controlled Clinical Trials.* John Wiley & Sons.

Whitehead A, Omar RZ, Higgins JPT, Savaluny E, Turner RM, Thompson SG (2001). Meta-analysis of ordinal outcomes using individual patient data. *Statistics in Medicine 20*, 2243-2260

Whitehead J (1993). Sample size calculations for ordered categorical data. *Statististcs in Medicine 12*, 2257-2271.

Whitehead J (1996). Sample sizes calculations for ordered categorical data. *Statistics in Medicine 15,* 1065-1066.

Wilcoxon F (1945). Individual comparisons by ranking methods. *Biometrics 1*, 80-83.

References – useful websites

The Cochrane Reviewer's handbook:
http://www.cochrane-handbook.org/

The Cochrane distance learning material
http://www.cochrane-net.org/openlearning/

The Cochrane RevMan user guide.
http://ims.cochrane.org/revman/documentation/rm5userguide.pdf (user guide)
http://ims.cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf (all the equations)

R meta analysis documentation.
http://rss.acs.unt.edu/Rdoc/library/rmeta/html/00Index.html

References – clinical examples used in presentations

The Abciximab in Ischemic Stroke Investigators (2000). Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose escalation study. *Stroke* 31, 601-609.

Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators (2005). Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial. *Stroke* 36, 880-890.

Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al (2008). Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). *Stroke* 39, 87-99.

Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, Fernandes J, Gogichaisvili T, Golden N, Hartzenberg B, Husain M, Ulloa MI, Jerbi Z, Khamis H, Komolafe E, Laloe V, Lomas G, Ludwig S, Mazairac G, Munoz Sanchez Mde L, Nasi L, Olldashi F, Plunkett P, Roberts I, Sandercock P, Shakur H, Soler C, Stocker R, Svoboda P, Trenkler S, Venkataramana NK, Wasserberg J, Yates D, Yutthakasemsunt S, CRASH trial collaborators (2005). Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. *Lancet* 365:1957-1959.

The FOOD trial collaboration (2005). Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. *Lancet* 365, 764-772.

Gennarelli TA, Spielman GM, Langfitt TW, Gildenberg PL, Harrington T, Jane JA, Marshall LF, Miller JD, Pitts LH (1982). Influence of the type of intracranial lesion on outcome from severe head injury. *Journal of Neurosurgery* 56, 26-32.

Hacke W, Kaste M, Fleschi C, Toni D, Lesaffre E, von Kummer R, et al (1995). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA* 274, 1017-1025.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al (2008). Thrombolysis with alteplase 3 to 4.5 hours after ischemic stroke. *New England Journal of Medicine* 359, 1317-1329.

Maas AI, Murray G, Henney H,3rd, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N, Pharmos TBI investigators (2006). Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. *Lancet Neurol* 5(1):38-45.

Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH, STICH investigators (2005). Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. *Lancet* 365:387-397.

Murray GD, Teasdale GM, Braakman R, Cohadon F, Dearden M, Iannotti F, Karimi A, Lapierre F, Maas A, Ohman J, Persson L, Servade IF, Stocchetti N, Trojanowski T, Unterberg A, on behalf of the European Brain Injury Consortium (1999). The European brain injury consortium survey of head injuries. *Acta Neurochirurgica* 141, 223-236.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischaemic stroke. *New England Journal of Medicine* 333(24), 1581-1587.

Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC (2008). Antiplatelet therapy for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*, Issue 3. Art. No.: CD000029. DOI: 10.1002/14651858.CD000029.pub2

Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloe V, Munoz-Sanchez A, Arango M, Hartzenberg B, Khamis H, Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards P, CRASH trial collaborators (2004). Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. *Lancet* 364:1321-1328.

Sandset EC, Bath PMW, Boysen G, Jatuzis D, Korv J, Luders S, Murray GD, Richter PS, Roine RO, Terent A, Thijs V, Berge E on behalf of the SCAST Study Group (2011). The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. *Lancet* 377: 741-750.

Wardlaw JM, Murray V, Berge E, del Zoppo GJ (2009). Thrombolysis for acute ischaemic stroke. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD000213. DOI: 10.1002/14651858.CD000213.pub2